A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
AstraZeneca
AstraZeneca
National Cancer Institute (NCI)
Hoffmann-La Roche
Merck Sharp & Dohme LLC
MedSIR
City of Hope Medical Center
Bayer
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
City of Hope Medical Center
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
University of Southern California
Novartis
Big Ten Cancer Research Consortium
AstraZeneca
Daiichi Sankyo
BicycleTx Limited
M.D. Anderson Cancer Center
Astellas Pharma Inc
Nanobiotix
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
Institut Paoli-Calmettes
Lund University Hospital
Valo Therapeutics Oy
Virginia Commonwealth University
Cedars-Sinai Medical Center
Merck Sharp & Dohme LLC
Fox Chase Cancer Center
Cedars-Sinai Medical Center
University Health Network, Toronto
Duke University
Providence Health & Services
University of California, San Francisco
NYU Langone Health
University of Malaya
Carisma Therapeutics Inc
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Adlai Nortye Biopharma Co., Ltd.
Institut fuer Frauengesundheit
University of Kansas Medical Center
NGM Biopharmaceuticals, Inc